Oncobiologics, Inc. (ONS) SEC Filing 8-K Material Event for the period ending Tuesday, August 28, 2018

Oncobiologics, Inc.

CIK: 1649989 Ticker: ONS

View differences made from one to another to evaluate Oncobiologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncobiologics, Inc..


Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ONS
CIK: 1649989
Form Type: 8-K Corporate News
Accession Number: 0001571049-18-000468
Submitted to the SEC: Tue Sep 04 2018 4:45:07 PM EST
Accepted by the SEC: Tue Sep 04 2018
Period: Tuesday, August 28, 2018
Industry: Biological Products No Disgnostic Substances
  1. Ending Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: